Biomarkers for precision therapy and prevention of type 2 diabetes - symposium
10-03-2020 14:00 - 17:00
Scania University Hospital
Jan Waldenströms gata 1
21428 - Malmö
The RHAPSODY Consortium groups 20 academic research laboratories focused especially on diabetes research (including 3 university hospitals with extensive experience following long-term diabetes cohorts and biobank), two SMEs (one specialised in lipid analyses and the other in scientific project management) and four well-established pharmaceutical and biotechnology establishments, all part of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HAPSODY (“Risk Assessment and ProgreSsiOn of DIabetes”), a public private consortium funded by the Innovative Medicines Initiative (IMI) and EFPIA Companies with contributions from academic institutions, has announced the launch of a project focused on assessing the risk of progression of pre-diabetes to overt diabetes and of rapid deterioration of type 2 diabetes (T2D), a pandemic disease, which currently affects 285 million people worldwide. It is anticipated that this number will rise sharply to affect 439 million people worldwide by 2030, in particular spreading to the younger population.
Leading European experts from 20 academic institutions, 4 EFPIA pharmaceutical organizations and two SMEs officially launched the IMI project RHAPSODY. IMI is a unique Public Private Partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations / EFPIA) and the European Union. The EU contributes a total of EUR 2.5 billion over ten years, which is matched by dedicated resources provided by EFPIA member companies.
RHAPSODY is a unique collaboration of leading public and private research groups, which will include over 100 researchers operating in 7 different scientific work packages. RHAPSODY is based on the availability of large population prospective cohorts, with unique collection of genetic, biochemical and clinical data. RHAPSODY will also beneficiate of extensive and unique resources developed in previous IMI projects. Combining new and existing data with the expertise of its partners, RHAPSODY will develop novel biomarkers to refine diagnosis leading to better patient stratification, promote prevention, and support innovative drug discovery for personalized management of diabetes.
The RHAPSODY team is coordinated by the University of Lausanne, Servier, Lund University and Sanofi and is working on a new definition of the molecular taxonomy of T2D diabetes that will support patient segmentation, inform clinical trial design, and enable the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
RHAPSODY brings together leading European experts, to identify, and characterize causal biomarkers for T2D subtypes and progression. Plans are built upon:
- Federated database
- Beta-cells and Insulin target tissue biomarkers
- Legal and economics - Expertise in regulatory approval, health economics and patient engagement. These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide
The close collaboration of academic teams, pharmaceutical companies and biotechs provides unique levels of expertise and forms a strong basis for reaching the ambitious RHAPSODY project goals.